Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Triple Negative Breast Neoplasms"" wg kryterium: Temat


Tytuł:
Tumor Microenvironment Can Predict Chemotherapy Response of Patients with Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
Autorzy:
Kim D; Interdisciplinary Program of Genomic Data Science, Pusan National University, Yangsan, Korea.
Yu Y; Biomedical Research Institute, Pusan National University School of Medicine, Yangsan, Korea.
Jung KS; Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea.
Kim YH; Periodontal Disease Signaling Network Research Center, Pusan National University School of Dentistry, Yangsan, Korea.; Department of Anatomy, Pusan National University School of Medicine, Yangsan, Korea.; Department of Biomedical Informatics, Pusan National University School of Medicine, Yangsan, Korea.
Kim JJ; Division of Hematology and Oncology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2024 Jan; Vol. 56 (1), pp. 162-177. Date of Electronic Publication: 2023 Jul 24.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Humans ; Neoadjuvant Therapy ; Tumor Microenvironment ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Prognosis
Czasopismo naukowe
Tytuł:
MnO 2 /Ce6 microbubble-mediated hypoxia modulation for enhancing sono-photodynamic therapy against triple negative breast cancer.
Autorzy:
Li P; Shenzhen Key Laboratory for Drug Addiction and Medication Safety, Department of Ultrasound, Institute of Ultrasonic Medicine, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, P.R. China. .
Tan X; Shenzhen Key Laboratory for Drug Addiction and Medication Safety, Department of Ultrasound, Institute of Ultrasonic Medicine, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, P.R. China. .; Zunyi Medical University, Zunyi 563000, P.R. China.
Dan Q; Shenzhen Key Laboratory for Drug Addiction and Medication Safety, Department of Ultrasound, Institute of Ultrasonic Medicine, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, P.R. China. .
Hu A; Shenzhen Key Laboratory for Drug Addiction and Medication Safety, Department of Ultrasound, Institute of Ultrasonic Medicine, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, P.R. China. .
Hu Z; Shenzhen Key Laboratory for Drug Addiction and Medication Safety, Department of Ultrasound, Institute of Ultrasonic Medicine, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, P.R. China. .
Yang X; Shenzhen Key Laboratory for Drug Addiction and Medication Safety, Department of Ultrasound, Institute of Ultrasonic Medicine, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, P.R. China. .
Bai J; Shenzhen Key Laboratory for Drug Addiction and Medication Safety, Department of Ultrasound, Institute of Ultrasonic Medicine, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, P.R. China. .
Chen X; Shenzhen Key Laboratory for Drug Addiction and Medication Safety, Department of Ultrasound, Institute of Ultrasonic Medicine, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, P.R. China. .
Li B; Department of Medical Imaging, Peking University Shenzhen Hospital, Shenzhen 518036, P.R. China.
Cheng G; Department of Medical Imaging, Peking University Shenzhen Hospital, Shenzhen 518036, P.R. China.
Liu L; Shenzhen Key Laboratory for Drug Addiction and Medication Safety, Department of Ultrasound, Institute of Ultrasonic Medicine, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, P.R. China. .
Chen Y; Shenzhen Key Laboratory for Drug Addiction and Medication Safety, Department of Ultrasound, Institute of Ultrasonic Medicine, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, P.R. China. .
Sun D; Shenzhen Key Laboratory for Drug Addiction and Medication Safety, Department of Ultrasound, Institute of Ultrasonic Medicine, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, P.R. China. .
Shuai X; Sun Yat-sen University, Guangzhou 510000, P.R. China. .
Zheng T; Shenzhen Key Laboratory for Drug Addiction and Medication Safety, Department of Ultrasound, Institute of Ultrasonic Medicine, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, P.R. China. .
Pokaż więcej
Źródło:
Biomaterials science [Biomater Sci] 2024 Mar 12; Vol. 12 (6), pp. 1465-1476. Date of Electronic Publication: 2024 Mar 12.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/diagnostic imaging
Triple Negative Breast Neoplasms*/drug therapy
Photochemotherapy*/methods
Porphyrins*/pharmacology
Humans ; Animals ; Mice ; Microbubbles ; Manganese Compounds ; Hydrogen Peroxide ; Cell Line, Tumor ; Oxides ; Photosensitizing Agents/pharmacology ; Photosensitizing Agents/therapeutic use ; Hypoxia ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Autorzy:
Baez-Navarro X; Department of Pathology, Erasmus University Medical Center, 3015 GD, Rotterdam, The Netherlands. .
van den Ende NS; Department of Pathology, Erasmus University Medical Center, 3015 GD, Rotterdam, The Netherlands.
Nguyen AH; Department of Pathology, Erasmus University Medical Center, 3015 GD, Rotterdam, The Netherlands.; Department of Pathology, HMC, The Hague, The Netherlands.
Sinke R; Department of Pathology, Pathan B.V., Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
Westenend P; Laboratory of Pathology, PAL Dordrecht, Dordrecht, The Netherlands.
van Brakel JB; Department of Pathology, Skåne University Hospital, Malmö, Sweden.
Stobbe C; Department of Pathology, Pathan B.V., Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
Westerga J; Department of Pathology, Pathan B.V., Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
van Deurzen CHM; Department of Pathology, Erasmus University Medical Center, 3015 GD, Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
Breast cancer research : BCR [Breast Cancer Res] 2024 Mar 11; Vol. 26 (1), pp. 41. Date of Electronic Publication: 2024 Mar 11.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/pathology
Breast Neoplasms*/pathology
Humans ; Female ; Lymphocytes, Tumor-Infiltrating/metabolism ; Biomarkers, Tumor/metabolism ; Retrospective Studies ; Neoadjuvant Therapy ; Prognosis ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Tytuł:
UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5.
Autorzy:
Li J; Department of Breast Surgery, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Liang Y; Department of Health Management & Institute of Health Management, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Zhou S; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China. .
Chen J; Department of Breast Surgery, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. .
Wu C; Department of Breast Surgery, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. .
Pokaż więcej
Źródło:
Breast cancer research : BCR [Breast Cancer Res] 2024 Mar 11; Vol. 26 (1), pp. 44. Date of Electronic Publication: 2024 Mar 11.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/metabolism
Humans ; Animals ; Cell Line, Tumor ; Promoter Regions, Genetic ; Cell Proliferation ; Mixed Function Oxygenases/genetics ; Mixed Function Oxygenases/metabolism ; Proto-Oncogene Proteins/genetics ; Ubiquitin Thiolesterase/genetics ; Ubiquitin Thiolesterase/metabolism ; Kruppel-Like Transcription Factors/genetics ; Kruppel-Like Transcription Factors/metabolism
Czasopismo naukowe
Tytuł:
Decreased Lung Metastasis in Triple Negative Breast Cancer Following Locally Delivered Supratherapeutic Paclitaxel-Loaded Polyglycerol Carbonate Nanoparticle Therapy.
Autorzy:
Sabatelle RC; Departments of Chemistry and Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.
Chu NQ; Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, United States.; Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Blessing W; Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Kharroubi H; Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Bressler E; Departments of Chemistry and Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.
Tsai L; Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, United States.
Shih A; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Grinstaff MW; Departments of Chemistry and Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.
Colson Y; Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, United States.; Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Pokaż więcej
Źródło:
Biomacromolecules [Biomacromolecules] 2024 Mar 11; Vol. 25 (3), pp. 1800-1809. Date of Electronic Publication: 2024 Feb 21.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/pathology
Lung Neoplasms*/drug therapy
Nanoparticles*
Glycerol*
Polymers*
Humans ; Female ; Paclitaxel ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Neoplasm Metastasis
Czasopismo naukowe
Tytuł:
Injectable Alginate Complex Hydrogel Loaded with Dual-Drug Nanovectors Offers Effective Photochemotherapy against Triple-Negative Breast Cancer.
Autorzy:
Lee YH; Department of Biomedical Sciences and Engineering, National Central University, Taoyuan City 320317, Taiwan R.O.C.; Department of Chemical and Materials Engineering, National Central University, Taoyuan City 320317, Taiwan R.O.C.
Lin CT; Department of Biomedical Sciences and Engineering, National Central University, Taoyuan City 320317, Taiwan R.O.C.
Pokaż więcej
Źródło:
Biomacromolecules [Biomacromolecules] 2024 Mar 11; Vol. 25 (3), pp. 2041-2051. Date of Electronic Publication: 2024 Feb 21.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/pathology
Photochemotherapy*
Nanoparticles*
Fluorocarbons*
Humans ; Mice ; Animals ; Hydrogels/therapeutic use ; Singlet Oxygen ; Phototherapy ; Indocyanine Green/pharmacology ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
Membrane-Cloaked Nanoparticles for RNA Interference of β-Catenin in Triple-Negative Breast Cancer.
Autorzy:
Scully MA; Department of Biomedical Engineering, University of Delaware, Newark, Delaware 19713, United States of America.
Wilhelm R; Department of Biomedical Engineering, University of Delaware, Newark, Delaware 19713, United States of America.
Wilkins DE; Department of Biomedical Engineering, University of Delaware, Newark, Delaware 19713, United States of America.
Day ES; Department of Biomedical Engineering, University of Delaware, Newark, Delaware 19713, United States of America.; Department of Materials Science and Engineering, University of Delaware, Newark, Delaware 19716, United States of America.; Center for Translational Research, Helen F. Graham Cancer Center and Research Institute, Newark, Delaware 19713, United States of America.
Pokaż więcej
Źródło:
ACS biomaterials science & engineering [ACS Biomater Sci Eng] 2024 Mar 11; Vol. 10 (3), pp. 1355-1363. Date of Electronic Publication: 2024 Feb 02.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/pathology
Nanoparticles*/therapeutic use
Humans ; RNA Interference ; beta Catenin/genetics ; beta Catenin/metabolism ; Cell Line, Tumor ; RNA, Small Interfering/genetics
Czasopismo naukowe
Tytuł:
TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication.
Autorzy:
Iachettini S; IRCCS - Regina Elena National Cancer Institute, Translational Oncology Research Unit, Via Elio Chianesi 53, 00144, Rome, Italy.
Terrenato I; IRCCS - Regina Elena National Cancer Institute, Clinical Trial Center, Biostatistics and Bioinformatics Unit, Via Elio Chianesi 53, 00144, Rome, Italy.
Porru M; IRCCS - Regina Elena National Cancer Institute, Translational Oncology Research Unit, Via Elio Chianesi 53, 00144, Rome, Italy.
Di Vito S; IRCCS - Regina Elena National Cancer Institute, Translational Oncology Research Unit, Via Elio Chianesi 53, 00144, Rome, Italy.
Rizzo A; IRCCS - Regina Elena National Cancer Institute, Translational Oncology Research Unit, Via Elio Chianesi 53, 00144, Rome, Italy.
D'Angelo C; IRCCS - Regina Elena National Cancer Institute, Translational Oncology Research Unit, Via Elio Chianesi 53, 00144, Rome, Italy.
Petti E; IRCCS - Regina Elena National Cancer Institute, Translational Oncology Research Unit, Via Elio Chianesi 53, 00144, Rome, Italy.
Dinami R; IRCCS - Regina Elena National Cancer Institute, Translational Oncology Research Unit, Via Elio Chianesi 53, 00144, Rome, Italy.
Maresca C; IRCCS - Regina Elena National Cancer Institute, Translational Oncology Research Unit, Via Elio Chianesi 53, 00144, Rome, Italy.
Di Benedetto A; IRCCS - Regina Elena National Cancer Institute, Pathology Unit, Via Elio Chianesi 53, Rome, Italy.
Palange A; IRCCS - Regina Elena National Cancer Institute, Pathology Unit, Via Elio Chianesi 53, Rome, Italy.
Mulè A; Pathology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Santoro A; Pathology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Palazzo A; Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Fuso P; Department of Woman and Child Health and Public Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Stoppacciaro A; Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Vici P; IRCCS - Regina Elena National Cancer Institute, Unit of Phase IV Trials, Via Elio Chianesi 53, Rome, Italy.
Filomeno L; IRCCS - Regina Elena National Cancer Institute, Unit of Phase IV Trials, Via Elio Chianesi 53, Rome, Italy.
Di Lisa FS; IRCCS - Regina Elena National Cancer Institute, Unit of Phase IV Trials, Via Elio Chianesi 53, Rome, Italy.
Arcuri T; IRCCS - Regina Elena National Cancer Institute, Unit of Phase IV Trials, Via Elio Chianesi 53, Rome, Italy.
Krasniqi E; IRCCS - Regina Elena National Cancer Institute, Unit of Phase IV Trials, Via Elio Chianesi 53, Rome, Italy.
Fabi A; Precision Medicine Unit in Senology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Biroccio A; IRCCS - Regina Elena National Cancer Institute, Translational Oncology Research Unit, Via Elio Chianesi 53, 00144, Rome, Italy. .
Zizza P; IRCCS - Regina Elena National Cancer Institute, Translational Oncology Research Unit, Via Elio Chianesi 53, 00144, Rome, Italy. .
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Mar 09; Vol. 43 (1), pp. 75. Date of Electronic Publication: 2024 Mar 09.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/pathology
Humans ; Animals ; Mice ; Retrospective Studies ; Taxoids/pharmacology ; Taxoids/therapeutic use ; Bridged-Ring Compounds/pharmacology ; Bridged-Ring Compounds/therapeutic use ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
Aryl hydrocarbon receptor suppresses STING-mediated type I IFN expression in triple-negative breast cancer.
Autorzy:
Martin JC; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
da Silva Fernandes T; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Chaudhry KA; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Breast Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Oshi M; Department of Breast Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Abrams SI; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Takabe K; Department of Breast Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Rosario SR; Department of Breast Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Bianchi-Smiraglia A; Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. .; Department of Breast Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 08; Vol. 14 (1), pp. 5731. Date of Electronic Publication: 2024 Mar 08.
Typ publikacji:
Journal Article
MeSH Terms:
Interferon Type I*/biosynthesis
Interferon Type I*/immunology
Interferon Type I*/metabolism
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/pathology
Humans ; BRCA2 Protein/genetics ; Receptors, Aryl Hydrocarbon/genetics
Czasopismo naukowe
Tytuł:
Targeting G-rich sequence to regulate the transcription of murine double minute (MDM) genes in triple-negative breast cancers.
Autorzy:
Feng Y; School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, China.
Xuan X; School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, China.
Hu Y; School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, China.
Lu J; School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, China.
Dong Z; School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, China.
Sun Z; School of Chemistry and Chemical Engineering, Yantai University, Yantai, 264005, China.
Yao H; School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, China.
Hu L; School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
Yin Q; School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, China. Electronic address: .
Liu Y; School of Chemistry and Chemical Engineering, Yantai University, Yantai, 264005, China.
Wang H; School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, China.
Pokaż więcej
Źródło:
European journal of medicinal chemistry [Eur J Med Chem] 2024 Mar 05; Vol. 267, pp. 116156. Date of Electronic Publication: 2024 Jan 25.
Typ publikacji:
Journal Article
MeSH Terms:
Proto-Oncogene Proteins c-mdm2*/metabolism
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/pathology
Humans ; Mice ; Animals ; Proto-Oncogene Proteins ; Nuclear Proteins/metabolism ; Cell Cycle Proteins/metabolism ; Tumor Suppressor Protein p53/metabolism
Czasopismo naukowe
Tytuł:
A novel tumor-associated neutrophil gene signature for predicting prognosis, tumor immune microenvironment, and therapeutic response in breast cancer.
Autorzy:
Zhang J; Department of Breast Disease, Weifang People's Hospital, Weifang, No.151, Guangwen Street, Kuiwen District, Shandong, China.
Wang X; Department of Breast Disease, Weifang People's Hospital, Weifang, No.151, Guangwen Street, Kuiwen District, Shandong, China.
Zhang Z; Department of General Surgery, Gaomi People's Hospital, Weifang, Shandong, China.
Ma F; Department of Breast Disease, Weifang People's Hospital, Weifang, No.151, Guangwen Street, Kuiwen District, Shandong, China.
Wang F; Department of Breast Disease, Weifang People's Hospital, Weifang, No.151, Guangwen Street, Kuiwen District, Shandong, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 04; Vol. 14 (1), pp. 5339. Date of Electronic Publication: 2024 Mar 04.
Typ publikacji:
Journal Article
MeSH Terms:
Neutrophils*
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/therapy
Humans ; Prognosis ; Genes, Neoplasm ; Area Under Curve ; Tumor Microenvironment/genetics
Czasopismo naukowe
Tytuł:
Synthesis of Self Permeable Antisense PMO Using C5-Guanidino-Functionalized Pyrimidines at the 5'-End Enables Sox2 Downregulation in Triple Negative Breast Cancer Cells.
Autorzy:
Das A; School of Applied and Interdisciplinary Sciences, Indian Association for the Cultivation of Science, Jadavpur, Kolkata 700032, India.
Gupta S; School of Applied and Interdisciplinary Sciences, Indian Association for the Cultivation of Science, Jadavpur, Kolkata 700032, India.
Shaw P; School of Applied and Interdisciplinary Sciences, Indian Association for the Cultivation of Science, Jadavpur, Kolkata 700032, India.
Sinha S; School of Applied and Interdisciplinary Sciences, Indian Association for the Cultivation of Science, Jadavpur, Kolkata 700032, India.
Pokaż więcej
Źródło:
Molecular pharmaceutics [Mol Pharm] 2024 Mar 04; Vol. 21 (3), pp. 1256-1271. Date of Electronic Publication: 2024 Feb 07.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/therapy
Humans ; Down-Regulation ; Pyrimidines ; Guanidine ; Morpholinos/chemistry ; Oligonucleotides
Czasopismo naukowe
Tytuł:
HER2-Low Status Was Associated With Better Breast Cancer-Specific Survival in Early-Stage Triple-Negative Breast Cancer.
Autorzy:
Ma Y; Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Jiao D; Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Zhang J; Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Lv M; Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Chen X; Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Liu Z; Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2024 Mar 04; Vol. 29 (3), pp. e309-e318.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/pathology
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/pathology
Humans ; Female ; Breast/pathology ; Prognosis ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism
Czasopismo naukowe
Tytuł:
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
Autorzy:
Smoots SG; Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA.
Schreiber AR; Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA.
Jackson MM; Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA.
Bagby SM; Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA.
Dominguez ATA; Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA.
Dus ED; Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA.
Binns CA; Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA.
MacBeth M; Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA.
Whitty PA; Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA.
Diamond JR; Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA.
Pitts TM; Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue MS8117, Aurora, CO, 80045, USA. .
Pokaż więcej
Źródło:
Breast cancer research : BCR [Breast Cancer Res] 2024 Mar 01; Vol. 26 (1), pp. 35. Date of Electronic Publication: 2024 Mar 01.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Histone Deacetylase Inhibitors*/pharmacology
Histone Deacetylase Inhibitors*/therapeutic use
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/metabolism
Humans ; Tumor Suppressor Protein p53/genetics ; Doxorubicin/pharmacology ; Doxorubicin/therapeutic use ; Apoptosis ; RNA, Small Interfering
Czasopismo naukowe
Tytuł:
Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
Autorzy:
Li J; Department of Gastrointestinal and Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Li Z; Department of Bone and Joint Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yang W; Department of Gastrointestinal and Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Pan J; Department of Gastrointestinal and Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
You H; Department of Gastrointestinal and Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yang L; Department of Gastrointestinal and Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Zhang X; Department of Gastrointestinal and Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Pokaż więcej
Źródło:
Cancer reports (Hoboken, N.J.) [Cancer Rep (Hoboken)] 2024 Mar; Vol. 7 (3), pp. e2007.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/therapy
Humans ; Immunogenic Cell Death ; Prognosis ; Immunotherapy ; Risk Factors ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer.
Autorzy:
Ou X; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Tan Y; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China.
Xie J; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Yuan J; Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Deng X; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Shao R; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Song C; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Cao X; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China.
Xie X; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
He R; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China. Electronic address: .
Li Y; The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China. Electronic address: .
Tang H; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. Electronic address: .
Pokaż więcej
Źródło:
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy [Drug Resist Updat] 2024 Mar; Vol. 73, pp. 101063. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Liver Neoplasms*/pathology
Humans ; Docetaxel/pharmacology ; Docetaxel/therapeutic use ; Ribosomal Protein S6 Kinases, 70-kDa ; Signal Transduction ; Methylation ; Receptors, G-Protein-Coupled/genetics ; TOR Serine-Threonine Kinases/genetics ; Mechanistic Target of Rapamycin Complex 1 ; Methyltransferases
Czasopismo naukowe
Tytuł:
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Autorzy:
Rusakiewicz S; Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland; Center of Experimental Therapeutics, Department of Oncology, University Hospital of Lausanne, 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, 1011 Lausanne, Switzerland.
Tyekucheva S; International Breast Cancer Study Group Statistical Center, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Tissot-Renaud S; Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland; Center of Experimental Therapeutics, Department of Oncology, University Hospital of Lausanne, 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, 1011 Lausanne, Switzerland.
Chaba K; Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland; Center of Experimental Therapeutics, Department of Oncology, University Hospital of Lausanne, 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, 1011 Lausanne, Switzerland.
Imbimbo M; Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Benedetti F; Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland; Center of Experimental Therapeutics, Department of Oncology, University Hospital of Lausanne, 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, 1011 Lausanne, Switzerland.
Kammler R; Translational Research Coordination, International Breast Cancer Study Group, a division of ETOP IBCSG Partners Foundation, Bern, Switzerland.
Hornfeld J; Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland; Center of Experimental Therapeutics, Department of Oncology, University Hospital of Lausanne, 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, 1011 Lausanne, Switzerland.
Munzone E; Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Gianni L; Department of Medical Oncology, Ospedale Infermi, AUSL Della Romagna, Rimini, Italy.
Thurlimann B; Kantonsspital St. Gallen, St Gallen, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.
Láng I; Clinexpert-research, Budapest, Hungary.
Pruneri G; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; University of Milan, School of Medicine, Milan, Italy.
Gray KP; Division of General Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Biostatistics and Research Design Core, Institutional Centers of Clinical and Translational Research, Boston Children's Hospital, Boston, MA, USA.
Regan MR; International Breast Cancer Study Group Statistical Center, Division of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Loi S; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Cancer Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; International Breast Cancer Study Group, a division of ETOP IBCSG Partners Foundation, Bern, Switzerland.
Colleoni M; Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy; Department of Pathology and Laboratory Medicine, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
Viale G; Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy; Department of Pathology and Laboratory Medicine, IEO, European Institute of Oncology, IRCCS, Milan, Italy; European Institute of Oncology, IRCCS, Milan, Italy.
Kandalaft L; Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland; Center of Experimental Therapeutics, Department of Oncology, University Hospital of Lausanne, 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, 1011 Lausanne, Switzerland.
Coukos G; Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland; Center of Experimental Therapeutics, Department of Oncology, University Hospital of Lausanne, 1011 Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, 1011 Lausanne, Switzerland.
Curigliano G; European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy. Electronic address: .
Pokaż więcej
Źródło:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Mar; Vol. 200, pp. 113535. Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/diagnostic imaging
Triple Negative Breast Neoplasms*/drug therapy
Humans ; Biomarkers, Tumor/analysis ; Cyclophosphamide ; Disease-Free Survival ; Forkhead Transcription Factors ; Lymphocytes, Tumor-Infiltrating ; Methotrexate ; Prognosis ; Female ; Randomized Controlled Trials as Topic ; Clinical Trials, Phase III as Topic
Czasopismo naukowe
Tytuł:
Estimating the risk and benefit of radiation therapy in (y)pN1 stage breast cancer patients: A Bayesian network model incorporating expert knowledge (KROG 22-13).
Autorzy:
Jang BS; Department of Radiation Oncology, Seoul National University Hospital, Seoul, South Korea; Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, South Korea.
Chun SJ; Department of Radiation Oncology, Seoul National University Hospital, Seoul, South Korea.
Choi HS; Department of Radiation Oncology, Seoul National University Hospital, Seoul, South Korea.
Chang JH; Department of Radiation Oncology, Seoul National University Hospital, Seoul, South Korea; Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, South Korea.
Shin KH; Department of Radiation Oncology, Seoul National University Hospital, Seoul, South Korea; Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, South Korea; Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, South Korea. Electronic address: .
Pokaż więcej
Corporate Authors:
Division for Breast Cancer, Korean Radiation Oncology Group
Źródło:
Computer methods and programs in biomedicine [Comput Methods Programs Biomed] 2024 Mar; Vol. 245, pp. 108049. Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/radiotherapy
Breast Neoplasms*/pathology
Triple Negative Breast Neoplasms*/pathology
Triple Negative Breast Neoplasms*/radiotherapy
Triple Negative Breast Neoplasms*/surgery
Humans ; Female ; Mastectomy/methods ; Bayes Theorem ; Neoplasm Staging ; Radiotherapy, Adjuvant/methods
Czasopismo naukowe
Tytuł:
Implication of IZUMO2 in the cell-in-cell phenomenon: A potential therapeutic target for triple-negative breast cancer.
Autorzy:
Higashi T; Department of Gastroenterological Surgery and Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan.
Saigo C; Department of Pathology and Translational Research, Gifu University Graduate School of Medicine, Gifu, Japan.; The United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.; Center for One Medicine Innovative Translational Research; COMIT, Gifu University, Gifu, Japan.
Chikaishi W; Department of Gastroenterological Surgery and Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan.
Hayashi H; Department of Gastroenterological Surgery and Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan.
Hanamatsu Y; Department of Pathology and Translational Research, Gifu University Graduate School of Medicine, Gifu, Japan.; Center for One Medicine Innovative Translational Research; COMIT, Gifu University, Gifu, Japan.
Futamura M; Department of Breast Surgery, Gifu University Hospital, Gifu, Japan.
Matsuhashi N; Department of Gastroenterological Surgery and Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan.
Takeuchi T; Department of Pathology and Translational Research, Gifu University Graduate School of Medicine, Gifu, Japan.; Center for One Medicine Innovative Translational Research; COMIT, Gifu University, Gifu, Japan.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Mar; Vol. 15 (7), pp. 513-518. Date of Electronic Publication: 2024 Jan 23.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Triple Negative Breast Neoplasms*/pathology
Male ; Humans ; Semen/metabolism ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Apoptosis ; Receptors, Estrogen/metabolism ; Cell Line, Tumor ; Cell Proliferation
Czasopismo naukowe
Tytuł:
A rare triple-negative breast cancer: The adenoid cystic carcinoma.
Autorzy:
Wu X; Hebei General Hospital (Department of Glandular Surgery), Shijiazhuang, Hebei, 050051, PR China; North China University of Science and Technology (School of Clinical Medicine), Tangshan, Hebei, 063000, PR China.
Zhang J; Hebei General Hospital (Department of Glandular Surgery), Shijiazhuang, Hebei, 050051, PR China; North China University of Science and Technology (School of Clinical Medicine), Tangshan, Hebei, 063000, PR China.
Yan X; Hebei General Hospital (Department of Glandular Surgery), Shijiazhuang, Hebei, 050051, PR China; North China University of Science and Technology (School of Clinical Medicine), Tangshan, Hebei, 063000, PR China.
Wang Y; Hebei General Hospital (Department of Glandular Surgery), Shijiazhuang, Hebei, 050051, PR China. Electronic address: .
Pokaż więcej
Źródło:
Asian journal of surgery [Asian J Surg] 2024 Mar; Vol. 47 (3), pp. 1485-1486. Date of Electronic Publication: 2023 Dec 12.
Typ publikacji:
Letter
MeSH Terms:
Carcinoma, Adenoid Cystic*/surgery
Carcinoma, Adenoid Cystic*/pathology
Triple Negative Breast Neoplasms*/therapy
Triple Negative Breast Neoplasms*/pathology
Breast Neoplasms*
Humans ; Female ; Biomarkers, Tumor
Opinia redakcyjna

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies